Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia

Inclusion Criteria: * Confirmed patient COVID19 positive with clinical signs of acute lower respiratory infection with signs of pneumonia or bronchitis: fever and / or cough and / or difficulty breathing in the absence of acute respiratory failure (PaO2\> 60 mmHg) with Plus or less : * Chills * Asthenia, fatigability * Headache * Arthromas myalgia * Dry throat * Rhinorrhea * An anosmia * chest pain * Diarrhea * Nausea and vomiting * Absence of rhythm disturbance (Qt interval \<500ms) * Patients hospitalized in the medical service * 18 years old \<Age \<80 years old * Having given written consent for their participation in the study Exclusion Criteria: * Allergy to macrolides, local anesthetics such as lidocaine or amide type and betalactamines * Take hydroxychloquine in the previous month * Severe / severe liver failure * Kidney failure (GFR \<30 ml / min / 1.73 m2) * Ongoing treatments with colchicine, ergot, rye, pimozide, mizolastine, simvastatin, lomitapide, alfuzosin, dapoxetine, avanafil, ivabradine, eplerenone, dronedarone, quetiapine, ticagrelor, cisapride, astemizole, terfenadine, ranolazine, domperidone. * Complete branch block * Hypovolemia * Retinopathy including vitreous involvement * Psoriasis * Pregnant or breastfeeding woman * hypersensitivity to chloroquine or hydroxychloroquine or to any of the other ingredients of this medication